CL2018002874A1 - Anticuerpos de hemaglutinina contra el virus de la influenza b y métodos de uso (divisional de solicitud n° 2413-2016). - Google Patents

Anticuerpos de hemaglutinina contra el virus de la influenza b y métodos de uso (divisional de solicitud n° 2413-2016).

Info

Publication number
CL2018002874A1
CL2018002874A1 CL2018002874A CL2018002874A CL2018002874A1 CL 2018002874 A1 CL2018002874 A1 CL 2018002874A1 CL 2018002874 A CL2018002874 A CL 2018002874A CL 2018002874 A CL2018002874 A CL 2018002874A CL 2018002874 A1 CL2018002874 A1 CL 2018002874A1
Authority
CL
Chile
Prior art keywords
methods
virus
antibodies against
divisional application
against influenza
Prior art date
Application number
CL2018002874A
Other languages
English (en)
Inventor
Min Xu
Ning Chai
Nancy Chiang
Henry Chiu
Zhonghua Lin
Gerald R Nakamura
Hyunjoo Park
Lee Swem
Mercedes Balazs
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CL2018002874A1 publication Critical patent/CL2018002874A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRESENTE INVENCIÓN PROPORCIONA ANTICUERPOS DE HEMAG)UTININA CONTRA EL VIRUS DE LA INFLUENZA B. COMPOSICIONES QUE COMPRENDEN ANTICUERPOS DE HEMAGLUTININA CONTRA E) VIRUS DE LA INFLUENZA B Y SUS MÉTODOS DE USO.
CL2018002874A 2014-03-27 2018-10-09 Anticuerpos de hemaglutinina contra el virus de la influenza b y métodos de uso (divisional de solicitud n° 2413-2016). CL2018002874A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461971123P 2014-03-27 2014-03-27

Publications (1)

Publication Number Publication Date
CL2018002874A1 true CL2018002874A1 (es) 2018-12-14

Family

ID=52829396

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2016002413A CL2016002413A1 (es) 2014-03-27 2016-09-26 Anticuerpos de hemaglutinina contra el virus de la influenza b y métodos de uso
CL2018002874A CL2018002874A1 (es) 2014-03-27 2018-10-09 Anticuerpos de hemaglutinina contra el virus de la influenza b y métodos de uso (divisional de solicitud n° 2413-2016).

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2016002413A CL2016002413A1 (es) 2014-03-27 2016-09-26 Anticuerpos de hemaglutinina contra el virus de la influenza b y métodos de uso

Country Status (20)

Country Link
US (2) US9745365B2 (es)
EP (1) EP3122771A1 (es)
JP (1) JP2017512471A (es)
KR (1) KR20160135830A (es)
CN (1) CN106132987A (es)
AR (1) AR099855A1 (es)
AU (1) AU2015235983A1 (es)
BR (1) BR112016022113A2 (es)
CA (1) CA2942820A1 (es)
CL (2) CL2016002413A1 (es)
CR (1) CR20160502A (es)
EA (1) EA201691945A1 (es)
IL (1) IL247870A0 (es)
MA (1) MA39803A (es)
MX (1) MX2016012530A (es)
PE (1) PE20161376A1 (es)
PH (1) PH12016501873A1 (es)
SG (1) SG11201607945UA (es)
TW (1) TW201620932A (es)
WO (1) WO2015148806A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018073133A2 (pt) 2016-05-10 2019-04-30 Genentech Inc métodos de diminuição das ligações trissulfeto durante a produção recombinante de polipeptídeos
IL275462B2 (en) 2017-12-22 2026-01-01 Genentech Inc Targeted integration of nucleic acids
KR102820941B1 (ko) 2018-01-26 2025-06-16 리제너론 파마슈티칼스 인코포레이티드 인플루엔자 헤마글루티닌에 대한 인간 항체
HRP20260157T1 (hr) 2018-03-29 2026-03-27 F. Hoffmann - La Roche Ag Moduliranje laktogene aktivnosti u stanicama sisavaca
AU2019403279A1 (en) 2018-12-21 2021-07-01 Genentech, Inc. Targeted integration of nucleic acids
RU2714246C1 (ru) * 2018-12-28 2020-02-13 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт гриппа имени А.А. Смородинцева" Министерства здравоохранения Российской Федерации Моноклональные антитела, специфичные к различным штаммам вируса гриппа в
CN114761428A (zh) * 2019-10-28 2022-07-15 瑞泽恩制药公司 抗血凝素抗体及其使用方法
AU2021210987A1 (en) * 2020-01-24 2022-08-04 Regeneron Pharmaceuticals, Inc. Protein-antiviral compound conjugates
KR20220159426A (ko) 2020-03-26 2022-12-02 제넨테크, 인크. 감소된 숙주 세포 단백질을 보유하는 변형된 포유동물 세포
US20220041672A1 (en) 2020-06-24 2022-02-10 Genentech, Inc. Apoptosis resistant cell lines
WO2021262798A1 (en) 2020-06-24 2021-12-30 Genentech, Inc. Targeted integration of nucleic acids
TW202227625A (zh) 2020-08-28 2022-07-16 美商建南德克公司 宿主細胞蛋白質之ＣＲＩＳＰＲ／Ｃａｓ９多重剔除
CN114316032B (zh) * 2020-09-27 2022-12-27 东莞市朋志生物科技有限公司 抗乙型流感病毒的抗体、检测乙型流感病毒的试剂和试剂盒
CA3215965A1 (en) 2021-04-19 2022-10-27 Amy Shen Modified mammalian cells
WO2022246259A1 (en) 2021-05-21 2022-11-24 Genentech, Inc. Modified cells for the production of a recombinant product of interest
JP2025537776A (ja) 2022-11-14 2025-11-20 ヤンセン ファッシンズ アンド プリベンション ベーフェー インフルエンザｂ型ウイルスワクチン及びその使用
IL320559A (en) 2022-11-15 2025-07-01 Genentech Inc Combining transposon-mediated integration and targeted integration of nucleic acids into host cells
JP2026502534A (ja) 2023-01-12 2026-01-23 ジェネンテック， インコーポレイテッド 核酸の標的組込みのためのコンビナトリアルベクターのクローニングおよびトランスフェクション戦略
US20250011420A1 (en) * 2023-07-03 2025-01-09 Medicovestor, Inc. Proteins that bind sp17 including fully-human anti-sp17 antibodies
US12319747B2 (en) 2023-07-03 2025-06-03 Medicovestor, Inc. Methods of using anti-SP17 immunotherapeutics
US12364777B2 (en) 2023-10-20 2025-07-22 Medicovestor, Inc. Homodimeric antibodies for use in treating cancers and methods of use
US12600795B2 (en) 2023-12-26 2026-04-14 Medicovestor, Inc. Oligomeric IgG for immunotherapeutics and diagnostics
US12116410B1 (en) 2023-12-26 2024-10-15 Medicovestor, Inc. Methods of manufacturing dimeric antibodies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2921928B1 (fr) 2007-10-08 2011-03-04 Sanofi Pasteur Anticorps monoclonaux specifiques de l'hemagglutinine du virus grippal
BE1018561A3 (fr) 2008-12-24 2011-03-01 Galactic Sa Procede de purification de l'acide lactique par cristallisation.
JP5780762B2 (ja) 2008-12-25 2015-09-16 国立大学法人大阪大学 抗ヒトインフルエンザウイルス・ヒト型抗体
DK2731967T3 (en) 2011-07-14 2017-01-16 Janssen Vaccines & Prevention Bv HUMAN BINDING MOLECULES CAPABLE OF NEUTRALIZING INFLUENZA A VIRUS FROM PHYLOGENETIC GROUP 1 AND PHYLOGENETIC GROUP 2 AND INFLUENZA B VIRUS
WO2013114885A1 (en) * 2012-01-31 2013-08-08 Osaka University Human monoclonal antibodies broadly protective against influenza b virus and methods of using the same
AU2013229488B2 (en) * 2012-03-08 2017-12-07 Janssen Vaccines & Prevention B.V. Human binding molecules capable of binding to and neutralizing influenza B viruses and uses thereof

Also Published As

Publication number Publication date
CL2016002413A1 (es) 2017-06-23
EP3122771A1 (en) 2017-02-01
AU2015235983A1 (en) 2016-10-06
BR112016022113A2 (pt) 2017-10-31
SG11201607945UA (en) 2016-10-28
JP2017512471A (ja) 2017-05-25
AR099855A1 (es) 2016-08-24
PH12016501873A1 (en) 2017-01-09
CN106132987A (zh) 2016-11-16
IL247870A0 (en) 2016-11-30
CR20160502A (es) 2017-02-03
PE20161376A1 (es) 2016-12-26
CA2942820A1 (en) 2015-10-01
WO2015148806A1 (en) 2015-10-01
EA201691945A1 (ru) 2017-02-28
US20170320937A1 (en) 2017-11-09
MA39803A (fr) 2017-02-01
MX2016012530A (es) 2017-01-05
TW201620932A (zh) 2016-06-16
KR20160135830A (ko) 2016-11-28
US9745365B2 (en) 2017-08-29
US20150274812A1 (en) 2015-10-01

Similar Documents

Publication Publication Date Title
CL2018002874A1 (es) Anticuerpos de hemaglutinina contra el virus de la influenza b y métodos de uso (divisional de solicitud n° 2413-2016).
CY1124215T1 (el) Μκ2 αναστολεις και χρησεις αυτων
MX2021006154A (es) Degradadores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
MX2017005920A (es) Anticuerpos anti-tim3 y metodos de uso.
CL2017001610A1 (es) Anticuerpos humanos para hemagglutinina de influenza
MX2017000395A (es) Vacunas contra virus influenza y usos de las mismas.
MX2017007049A (es) Anticuerpos anti-cd79b y métodos de uso.
MX2017015464A (es) Anticuerpos anti-tau y metodos de uso.
MX2018007288A (es) Anticuerpos neutralizantes para el virus de inmunodeficiencia humana.
CR20190271A (es) Anticuerpos antitau y métodos de uso
MX2024011869A (es) Anticuerpos anti-tau y metodos de uso
EA201692541A1 (ru) Вакцины против вируса гриппа и их применения
BR112017008666A2 (pt) anticorpos anti-fgfr2/3 e métodos de uso dos mesmos
MX2016014247A (es) Conjugados de anticuerpo-farmaco anti-proteina tirosina quinasa 7 (anti-ptk7).
BR112016022658A2 (pt) anticorpos anti-ox40 e métodos de uso
CR20160362A (es) Anticuerpos anti-jagged1 y metodos de uso
CY1124338T1 (el) Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων
MX389001B (es) Moduladores de interacción de sestrina-gator2 y sus usos.
CL2019000049A1 (es) Procesos para la preparación de oxipicolinamidas 4 - alkoxi - (acil o aquil).
EA201991377A1 (ru) Композиции универсальной вакцины против гриппа
UY36221A (es) Derivados de isoindolinona
MX2016015280A (es) Anticuerpos anti-bromodesoxiuridina(brdu) y metodos de uso.
MX2016016233A (es) Anticuerpos anti-lgr5 y sus usos.
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.
MX2018005153A (es) Composicion adhesiva mejorada.